Last reviewed · How we verify

NCT04252638

Acceptance and Commitment Therapy as a New Treatment for Adults With Insomnia Disorder

Completed NA Last updated 9 March 2023
What this trial tests

NA trial testing Acceptance and Commitment Therapy plus Sleep Restriction in Insomnia Chronic in 60 participants. Completed in 1 May 2022.

Timeline
13 January 2020
Primary endpoint
1 May 2022
1 May 2022

Quick facts

Lead sponsorUniversity of Bern
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date13 January 2020
Primary completion1 May 2022
Estimated completion1 May 2022
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University of Bern

Who can join

Adults 18 to 75, any sex, with Insomnia Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acceptance and Commitment Therapy plus sleep restriction (ACT) will be compared to Cognitive Behavioral Therapy for insomnia (CBT-I). CBT-I is the first line treatment for insomnia according to current guidelines. The aim of the study is to investigate the efficacy of ACT, compared to CBT-I, for the improvement of sleep-related quality of life and insomnia severity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Insomnia Chronic

Currently open trials in the same condition.

Other University of Bern trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04252638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing